The Guardian: Hepatitis C medicines must be made accessible faster than HIV drugs were
Philippe Douste-Blazy, chair of UNITAID and special adviser to the U.N. secretary general on innovative financing

“… Until recently, the only cure for hepatitis C involved an expensive combination of injections and tablets that lasted a year. In addition to having limited efficacy, this regimen caused serious side effects that deterred patients from finishing the full course. Now, new drugs are poised to enter the market that work more quickly, are more effective, and may not require weekly injections. … Governments, pharmaceuticals, and civil society must work together. We need to learn from our experience with HIV and AIDS and negotiate better prices from all manufacturers. Generic competition should be encouraged to bring prices down…” (3/7).